{"id":799264,"date":"2025-01-09T09:03:37","date_gmt":"2025-01-09T14:03:37","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/exelixis-provides-update-on-oncologic-drugs-advisory-committee-meeting-for-cabozantinib-cabometyx-for-the-treatment-of-patients-with-previously-treated-advanced-neuroendocrine-tumors\/"},"modified":"2025-01-09T09:03:37","modified_gmt":"2025-01-09T14:03:37","slug":"exelixis-provides-update-on-oncologic-drugs-advisory-committee-meeting-for-cabozantinib-cabometyx-for-the-treatment-of-patients-with-previously-treated-advanced-neuroendocrine-tumors","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/exelixis-provides-update-on-oncologic-drugs-advisory-committee-meeting-for-cabozantinib-cabometyx-for-the-treatment-of-patients-with-previously-treated-advanced-neuroendocrine-tumors\/","title":{"rendered":"Exelixis Provides Update on Oncologic Drugs Advisory Committee Meeting for Cabozantinib (CABOMETYX\u00ae) for the Treatment of Patients with Previously Treated Advanced Neuroendocrine Tumors"},"content":{"rendered":"

<\/p>\n

Exelixis Provides Update on Oncologic Drugs Advisory Committee Meeting for Cabozantinib (CABOMETYX\u00ae<\/sup>) for the Treatment of Patients with Previously Treated Advanced Neuroendocrine Tumors<\/b><\/p>\n

ALAMEDA, Calif.–(BUSINESS WIRE<\/a>)–Exelixis, Inc.<\/a> (Nasdaq: EXEL) today announced it has been notified by the U.S. Food and Drug Administration (FDA) that the supplemental New Drug Application (sNDA) for cabozantinib (CABOMETYX\u00ae<\/sup>) for the treatment of adults with previously treated advanced pancreatic neuroendocrine tumors (pNET) and advanced extra-pancreatic (epNET) will no longer be the subject of discussion at an Oncologic Drugs Advisory Committee meeting. The sNDA remains under consideration by FDA with a Prescription Drug User Fee Act action date of April 3, 2025.<\/p>\n

About Exelixis
\n
<\/b>Exelixis is a globally ambitious oncology company innovating next-generation medicines and regimens at the forefront of cancer care. Powered by drug discovery and development excellence, we are rapidly evolving our product portfolio to target an expanding range of tumor types and indications with our clinically differentiated pipeline of small molecules, antibody-drug conjugates and other biotherapeutics. This comprehensive approach harnesses decades of robust investment in our science and partnerships to advance our investigational programs and extend the impact of our flagship commercial product, CABOMETYX\u00ae<\/sup> (cabozantinib). Exelixis is driven by a bold scientific pursuit to create transformational treatments that give more patients hope for the future. For information about the company and its mission to help cancer patients recover stronger and live longer, visit www.exelixis.com<\/a>, follow @ExelixisInc<\/a> on X (Twitter), like Exelixis, Inc.<\/a> on Facebook and follow Exelixis<\/a> on LinkedIn.<\/p>\n

Exelixis Forward-Looking Statements
\n
<\/b>This press release contains forward-looking statements, including, without limitation, statements related to: the FDA\u2019s plans to discuss the sNDA for cabozantinib for the treatment of adults with previously treated advanced pNET and advanced epNET at an ODAC meeting; the therapeutic potential of cabozantinib as a treatment for patients with previously treated advanced pNET and advanced epNET; the regulatory review process with respect to Exelixis\u2019 sNDA for cabozantinib in previously treated advanced pNET and advanced epNET, including the Prescription Drug User Fee Act target action date assigned by the FDA; and Exelixis\u2019 scientific pursuit to create transformational treatments that give patients more hope for the future. Any statements that refer to expectations, projections or other characterizations of future events or circumstances are forward-looking statements and are based upon Exelixis\u2019 current plans, assumptions, beliefs, expectations, estimates and projections. Forward-looking statements involve risks and uncertainties. Actual results and the timing of events could differ materially from those anticipated in the forward-looking statements as a result of these risks and uncertainties, which include, without limitation: complexities and the unpredictability of the regulatory review and approval processes in the U.S. and elsewhere, including the risk that the FDA may not approve cabozantinib as a treatment for pNET or epNET in a timely fashion, if at all; unexpected concerns that may arise as a result of the occurrence of adverse safety events or additional data analyses of clinical trials evaluating cabozantinib; Exelixis\u2019 ability to protect its intellectual property rights; market competition, including the potential for competitors to obtain approval for generic versions of CABOMETYX; changes in economic and business conditions; and other factors affecting the ability of Exelixis to obtain regulatory approval for cabozantinib in new indications detailed from time to time under the caption \u201cRisk Factors\u201d in Exelixis\u2019 most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q, and in Exelixis\u2019 future filings with the Securities and Exchange Commission. All forward-looking statements in this press release are based on information available to Exelixis as of the date of this press release, and Exelixis undertakes no obligation to update or revise any forward-looking statements contained herein, except as required by law.<\/p>\n

Exelixis, the Exelixis logo and CABOMETYX are registered U.S. trademarks of Exelixis.<\/i><\/p>\n

\"\"<\/p>\n

View source version on businesswire.com: <\/span>https:\/\/www.businesswire.com\/news\/home\/20250109096110\/en\/<\/a><\/span><\/p>\n

Investors:
\n<\/b>
Susan Hubbard
\n<\/i>
EVP, Public Affairs and
\n
Investor Relations
\n<\/i>
Exelixis, Inc.
\n<\/i>
(650) 837-8194
\n<\/i>
shubbard@exelixis.com<\/i><\/a><\/p>\n

Media:
\n<\/b>
Claire McConnaughey
\n<\/i>
Senior Director, Public Affairs
\n<\/i>
Exelixis, Inc.
\n<\/i>
(650) 837-7052
\n<\/i>
cmcconn@exelixis.com<\/i><\/a><\/p>\n

KEYWORDS:<\/b> California United States North America<\/p>\n

INDUSTRY KEYWORDS:<\/b> FDA Pharmaceutical Health Oncology<\/p>\n

MEDIA:<\/b><\/p>\n\n\n\n\n
Logo<\/b><\/font><\/td>\n<\/tr>\n
\"Logo\"<\/td>\n<\/tr>\n
<\/font><\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"

Exelixis Provides Update on Oncologic Drugs Advisory Committee Meeting for Cabozantinib (CABOMETYX\u00ae) for the Treatment of Patients with Previously Treated Advanced Neuroendocrine Tumors ALAMEDA, Calif.–(BUSINESS WIRE)–Exelixis, Inc. (Nasdaq: EXEL) today announced it has been notified by the U.S. Food and Drug Administration (FDA) that the supplemental New Drug Application (sNDA) for cabozantinib (CABOMETYX\u00ae) for the treatment of adults with previously treated advanced pancreatic neuroendocrine tumors (pNET) and advanced extra-pancreatic (epNET) will no longer be the subject of discussion at an Oncologic Drugs Advisory Committee meeting. The sNDA remains under consideration by FDA with a Prescription Drug User Fee Act action date of April 3, 2025. About Exelixis Exelixis is a globally ambitious oncology company innovating next-generation medicines and regimens at … <\/p>\n

Continue reading “Exelixis Provides Update on Oncologic Drugs Advisory Committee Meeting for Cabozantinib (CABOMETYX\u00ae) for the Treatment of Patients with Previously Treated Advanced Neuroendocrine Tumors”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-799264","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nExelixis Provides Update on Oncologic Drugs Advisory Committee Meeting for Cabozantinib (CABOMETYX\u00ae) for the Treatment of Patients with Previously Treated Advanced Neuroendocrine Tumors - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/exelixis-provides-update-on-oncologic-drugs-advisory-committee-meeting-for-cabozantinib-cabometyx-for-the-treatment-of-patients-with-previously-treated-advanced-neuroendocrine-tumors\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Exelixis Provides Update on Oncologic Drugs Advisory Committee Meeting for Cabozantinib (CABOMETYX\u00ae) for the Treatment of Patients with Previously Treated Advanced Neuroendocrine Tumors - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Exelixis Provides Update on Oncologic Drugs Advisory Committee Meeting for Cabozantinib (CABOMETYX\u00ae) for the Treatment of Patients with Previously Treated Advanced Neuroendocrine Tumors ALAMEDA, Calif.–(BUSINESS WIRE)–Exelixis, Inc. (Nasdaq: EXEL) today announced it has been notified by the U.S. Food and Drug Administration (FDA) that the supplemental New Drug Application (sNDA) for cabozantinib (CABOMETYX\u00ae) for the treatment of adults with previously treated advanced pancreatic neuroendocrine tumors (pNET) and advanced extra-pancreatic (epNET) will no longer be the subject of discussion at an Oncologic Drugs Advisory Committee meeting. The sNDA remains under consideration by FDA with a Prescription Drug User Fee Act action date of April 3, 2025. About Exelixis Exelixis is a globally ambitious oncology company innovating next-generation medicines and regimens at … Continue reading "Exelixis Provides Update on Oncologic Drugs Advisory Committee Meeting for Cabozantinib (CABOMETYX\u00ae) for the Treatment of Patients with Previously Treated Advanced Neuroendocrine Tumors"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/exelixis-provides-update-on-oncologic-drugs-advisory-committee-meeting-for-cabozantinib-cabometyx-for-the-treatment-of-patients-with-previously-treated-advanced-neuroendocrine-tumors\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-01-09T14:03:37+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20250109096110r1&sid=flmnd&distro=nx&lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/exelixis-provides-update-on-oncologic-drugs-advisory-committee-meeting-for-cabozantinib-cabometyx-for-the-treatment-of-patients-with-previously-treated-advanced-neuroendocrine-tumors\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/exelixis-provides-update-on-oncologic-drugs-advisory-committee-meeting-for-cabozantinib-cabometyx-for-the-treatment-of-patients-with-previously-treated-advanced-neuroendocrine-tumors\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Exelixis Provides Update on Oncologic Drugs Advisory Committee Meeting for Cabozantinib (CABOMETYX\u00ae) for the Treatment of Patients with Previously Treated Advanced Neuroendocrine Tumors\",\"datePublished\":\"2025-01-09T14:03:37+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/exelixis-provides-update-on-oncologic-drugs-advisory-committee-meeting-for-cabozantinib-cabometyx-for-the-treatment-of-patients-with-previously-treated-advanced-neuroendocrine-tumors\\\/\"},\"wordCount\":704,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/exelixis-provides-update-on-oncologic-drugs-advisory-committee-meeting-for-cabozantinib-cabometyx-for-the-treatment-of-patients-with-previously-treated-advanced-neuroendocrine-tumors\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20250109096110r1&sid=flmnd&distro=nx&lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/exelixis-provides-update-on-oncologic-drugs-advisory-committee-meeting-for-cabozantinib-cabometyx-for-the-treatment-of-patients-with-previously-treated-advanced-neuroendocrine-tumors\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/exelixis-provides-update-on-oncologic-drugs-advisory-committee-meeting-for-cabozantinib-cabometyx-for-the-treatment-of-patients-with-previously-treated-advanced-neuroendocrine-tumors\\\/\",\"name\":\"Exelixis Provides Update on Oncologic Drugs Advisory Committee Meeting for Cabozantinib (CABOMETYX\u00ae) for the Treatment of Patients with Previously Treated Advanced Neuroendocrine Tumors - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/exelixis-provides-update-on-oncologic-drugs-advisory-committee-meeting-for-cabozantinib-cabometyx-for-the-treatment-of-patients-with-previously-treated-advanced-neuroendocrine-tumors\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/exelixis-provides-update-on-oncologic-drugs-advisory-committee-meeting-for-cabozantinib-cabometyx-for-the-treatment-of-patients-with-previously-treated-advanced-neuroendocrine-tumors\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20250109096110r1&sid=flmnd&distro=nx&lang=en\",\"datePublished\":\"2025-01-09T14:03:37+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/exelixis-provides-update-on-oncologic-drugs-advisory-committee-meeting-for-cabozantinib-cabometyx-for-the-treatment-of-patients-with-previously-treated-advanced-neuroendocrine-tumors\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/exelixis-provides-update-on-oncologic-drugs-advisory-committee-meeting-for-cabozantinib-cabometyx-for-the-treatment-of-patients-with-previously-treated-advanced-neuroendocrine-tumors\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/exelixis-provides-update-on-oncologic-drugs-advisory-committee-meeting-for-cabozantinib-cabometyx-for-the-treatment-of-patients-with-previously-treated-advanced-neuroendocrine-tumors\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20250109096110r1&sid=flmnd&distro=nx&lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20250109096110r1&sid=flmnd&distro=nx&lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/exelixis-provides-update-on-oncologic-drugs-advisory-committee-meeting-for-cabozantinib-cabometyx-for-the-treatment-of-patients-with-previously-treated-advanced-neuroendocrine-tumors\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Exelixis Provides Update on Oncologic Drugs Advisory Committee Meeting for Cabozantinib (CABOMETYX\u00ae) for the Treatment of Patients with Previously Treated Advanced Neuroendocrine Tumors\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Exelixis Provides Update on Oncologic Drugs Advisory Committee Meeting for Cabozantinib (CABOMETYX\u00ae) for the Treatment of Patients with Previously Treated Advanced Neuroendocrine Tumors - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/exelixis-provides-update-on-oncologic-drugs-advisory-committee-meeting-for-cabozantinib-cabometyx-for-the-treatment-of-patients-with-previously-treated-advanced-neuroendocrine-tumors\/","og_locale":"en_US","og_type":"article","og_title":"Exelixis Provides Update on Oncologic Drugs Advisory Committee Meeting for Cabozantinib (CABOMETYX\u00ae) for the Treatment of Patients with Previously Treated Advanced Neuroendocrine Tumors - Market Newsdesk","og_description":"Exelixis Provides Update on Oncologic Drugs Advisory Committee Meeting for Cabozantinib (CABOMETYX\u00ae) for the Treatment of Patients with Previously Treated Advanced Neuroendocrine Tumors ALAMEDA, Calif.–(BUSINESS WIRE)–Exelixis, Inc. (Nasdaq: EXEL) today announced it has been notified by the U.S. Food and Drug Administration (FDA) that the supplemental New Drug Application (sNDA) for cabozantinib (CABOMETYX\u00ae) for the treatment of adults with previously treated advanced pancreatic neuroendocrine tumors (pNET) and advanced extra-pancreatic (epNET) will no longer be the subject of discussion at an Oncologic Drugs Advisory Committee meeting. The sNDA remains under consideration by FDA with a Prescription Drug User Fee Act action date of April 3, 2025. About Exelixis Exelixis is a globally ambitious oncology company innovating next-generation medicines and regimens at … Continue reading \"Exelixis Provides Update on Oncologic Drugs Advisory Committee Meeting for Cabozantinib (CABOMETYX\u00ae) for the Treatment of Patients with Previously Treated Advanced Neuroendocrine Tumors\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/exelixis-provides-update-on-oncologic-drugs-advisory-committee-meeting-for-cabozantinib-cabometyx-for-the-treatment-of-patients-with-previously-treated-advanced-neuroendocrine-tumors\/","og_site_name":"Market Newsdesk","article_published_time":"2025-01-09T14:03:37+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20250109096110r1&sid=flmnd&distro=nx&lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/exelixis-provides-update-on-oncologic-drugs-advisory-committee-meeting-for-cabozantinib-cabometyx-for-the-treatment-of-patients-with-previously-treated-advanced-neuroendocrine-tumors\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/exelixis-provides-update-on-oncologic-drugs-advisory-committee-meeting-for-cabozantinib-cabometyx-for-the-treatment-of-patients-with-previously-treated-advanced-neuroendocrine-tumors\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Exelixis Provides Update on Oncologic Drugs Advisory Committee Meeting for Cabozantinib (CABOMETYX\u00ae) for the Treatment of Patients with Previously Treated Advanced Neuroendocrine Tumors","datePublished":"2025-01-09T14:03:37+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/exelixis-provides-update-on-oncologic-drugs-advisory-committee-meeting-for-cabozantinib-cabometyx-for-the-treatment-of-patients-with-previously-treated-advanced-neuroendocrine-tumors\/"},"wordCount":704,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/exelixis-provides-update-on-oncologic-drugs-advisory-committee-meeting-for-cabozantinib-cabometyx-for-the-treatment-of-patients-with-previously-treated-advanced-neuroendocrine-tumors\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20250109096110r1&sid=flmnd&distro=nx&lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/exelixis-provides-update-on-oncologic-drugs-advisory-committee-meeting-for-cabozantinib-cabometyx-for-the-treatment-of-patients-with-previously-treated-advanced-neuroendocrine-tumors\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/exelixis-provides-update-on-oncologic-drugs-advisory-committee-meeting-for-cabozantinib-cabometyx-for-the-treatment-of-patients-with-previously-treated-advanced-neuroendocrine-tumors\/","name":"Exelixis Provides Update on Oncologic Drugs Advisory Committee Meeting for Cabozantinib (CABOMETYX\u00ae) for the Treatment of Patients with Previously Treated Advanced Neuroendocrine Tumors - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/exelixis-provides-update-on-oncologic-drugs-advisory-committee-meeting-for-cabozantinib-cabometyx-for-the-treatment-of-patients-with-previously-treated-advanced-neuroendocrine-tumors\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/exelixis-provides-update-on-oncologic-drugs-advisory-committee-meeting-for-cabozantinib-cabometyx-for-the-treatment-of-patients-with-previously-treated-advanced-neuroendocrine-tumors\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20250109096110r1&sid=flmnd&distro=nx&lang=en","datePublished":"2025-01-09T14:03:37+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/exelixis-provides-update-on-oncologic-drugs-advisory-committee-meeting-for-cabozantinib-cabometyx-for-the-treatment-of-patients-with-previously-treated-advanced-neuroendocrine-tumors\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/exelixis-provides-update-on-oncologic-drugs-advisory-committee-meeting-for-cabozantinib-cabometyx-for-the-treatment-of-patients-with-previously-treated-advanced-neuroendocrine-tumors\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/exelixis-provides-update-on-oncologic-drugs-advisory-committee-meeting-for-cabozantinib-cabometyx-for-the-treatment-of-patients-with-previously-treated-advanced-neuroendocrine-tumors\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20250109096110r1&sid=flmnd&distro=nx&lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20250109096110r1&sid=flmnd&distro=nx&lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/exelixis-provides-update-on-oncologic-drugs-advisory-committee-meeting-for-cabozantinib-cabometyx-for-the-treatment-of-patients-with-previously-treated-advanced-neuroendocrine-tumors\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Exelixis Provides Update on Oncologic Drugs Advisory Committee Meeting for Cabozantinib (CABOMETYX\u00ae) for the Treatment of Patients with Previously Treated Advanced Neuroendocrine Tumors"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/799264","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=799264"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/799264\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=799264"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=799264"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=799264"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}